$Lucid Diagnostics(LUCD.US)$Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data From National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing PR Newswire· 2 mins ago
$Lucid Diagnostics(LUCD.US)$ NEWS Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing The peer-reviewed publication of positive data from a National Cancer Institute-sponsored study enhances Lucid Diagnostics' reputation and credibility in the medical diagnostics field. EsoGuard's demonstration of unprecedented early precancer detection with 89...
$Lucid Diagnostics(LUCD.US)$Lucid Diagnostics posted Q4 revenues of $1 million, marking a 33% increase from Q3 and a 829% increase annually. Non-GAAP net loss for the quarter was $9.9 million, showing a slight increase from Q3 but a year-over-year decrease of $700,000. The company had a year-end cash balance of $18.9 million, supported by a recent financing of $18.1 million. Approximately 50% of the claims submitted have been adjudicated, with an averaging payment of $1,800. The projected re...
$Lucid Diagnostics(LUCD.US)$Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors PR Newswire· 1 min ago The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participants at almost 2.5K per billable test
Lucid Diagnostics股票討論區
PR Newswire· 2 mins ago
NEWS
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
The peer-reviewed publication of positive data from a National Cancer Institute-sponsored study enhances Lucid Diagnostics' reputation and credibility in the medical diagnostics field.
EsoGuard's demonstration of unprecedented early precancer detection with 89...
Non-GAAP net loss for the quarter was $9.9 million, showing a slight increase from Q3 but a year-over-year decrease of $700,000.
The company had a year-end cash balance of $18.9 million, supported by a recent financing of $18.1 million.
Approximately 50% of the claims submitted have been adjudicated, with an averaging payment of $1,800.
The projected re...
PR Newswire· 1 min ago
The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participants at almost 2.5K per billable test
Dow Jones· 1 min ago
5月9日週二,美股集體低開低走,地區銀行股指數走低。開盤一小時,道指短暫轉漲後再度轉跌,納指跌0.5%與羅素2000小盤股跌近1%均領跌主要指數。
午盤時,標普500指數、道指和納指均刷新日低,分別跌0.5%、跌近110點和跌0.7%。臨近尾盤時道指幾度轉漲,最終仍與其他指數一同收跌,納指收盤接近日低。
截至收盤,標普、納指和納指100均止步兩日連漲,道指連跌兩日,納指失守去年9月12日以來的近八個月最高,納指100失守去年8月18日以來的近九個月最高:
$標普500指數(.SPX.US)$ 收跌18.95點,跌幅0.46%,報4119.17點。 $道瓊斯指數(.DJI.US)$ 收跌56.88點,跌幅0.17%,報33561.81點。 $納斯達克綜合指數(.IXIC.US)$ 收跌77.36點,跌幅0.63%,報12179.55點。 $納指100ETF-Invesco QQQ Trust(QQQ.US)$ 跌0.7%, ...
By Danilo
$InnovAge Holding(INNV.US)$ $Lucid Diagnostics(LUCD.US)$ $Innovid(CTV.US)$ $切薩皮克能源(CHK.US)$
暫無評論